Bone drug lowers breast cancer risk 38% in high-risk women


April 20, 2010

USA Today

A common osteoporosis drug, raloxifene, reduces breast cancer risk by 38% in women at high risk for the disease, without causing the serious side effects of similar drugs, a new study shows.

That suggests more high-risk women should consider taking raloxifene, also known as Evista, says Victor Vogel, main author of the study presented Monday at the American Association for Cancer Research meeting in Washington... read more